Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.

摘要: Abstract Background Streptococcus pneumoniae causes community-acquired pneumonia, otitis media and meningitis, with higher incidences at the extremes of life. PPV-23 vaccine is widely used in prevention pneumonia invasive pneumococcal disease older adults developed countries. We an evaluation cost-effectiveness implementing Colombian population over 60 years. Methods The number cases meningitis patients years proportion by S. was estimated based on a review literature. A decision tree model 5-year time horizon built to evaluate implementation this population. Direct health care costs out- in-patients were calculated expenditure records from Bogota public system. Incremental ratios per life saved year gained model. Deterministic probabilistic sensitivity analyses performed. Results Without vaccination 4460 (range 2384–8162) bacteremic pneumonias 141 73–183) would occur among people old Colombia. In first year, US$8/dose save 480 100–1753) deaths due Invasive non-invasive disease. Vaccination results US$3400/deaths averted US$1028–10,862) US$1514/life US$408–5404). Conclusion highly cost-effective measure Despite some limitations, are robust, may help developing countries perform informed decisions about introduction vaccine.